Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Deloitte
Colorcon
Chubb
Cerilliant
Healthtrust
Boehringer Ingelheim
Fuji
Medtronic
Covington

Generated: October 24, 2017

DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and seven approved drugs.

There are seventy-two US patents protecting TEVA drugs and there have been two Paragraph IV challenges on TEVA drugs in the past three years. There are forty-three tentative approvals on TEVA drugs.

There are eight hundred and ninety patent family members on TEVA drugs in fifty-two countries and four hundred and eighty-four supplementary protection certificates in fourteen countries.

Summary for Applicant: Teva

International Patents:890
US Patents:72
Tradenames:467
Ingredients:409
NDAs:707
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva
LOVASTATIN
lovastatin
TABLET;ORAL075551-001Dec 17, 2001ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharm
ARMONAIR RESPICLICK
fluticasone propionate
POWDER;INHALATION208798-002Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077587-001Jul 9, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Parenteral
NEOSAR
cyclophosphamide
INJECTABLE;INJECTION040015-002Apr 29, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE
granisetron hydrochloride
INJECTABLE;INJECTION077165-001Dec 31, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva
FEXOFENADINE HYDROCHLORIDE ALLERGY
fexofenadine hydrochloride
TABLET;ORAL076447-008Apr 13, 2011OTCNoNo► Subscribe► Subscribe► Subscribe
Teva
ROSIGLITAZONE MALEATE
rosiglitazone maleate
TABLET;ORAL076747-001Jan 25, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
CENESTIN
estrogens, conjugated synthetic a
TABLET;ORAL020992-003Mar 24, 1999DISCNYesNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-003Apr 3, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Teva
AMOXICILLIN
amoxicillin
CAPSULE;ORAL063031-001Feb 28, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Branded Pharm
NORDETTE-28
ethinyl estradiol; levonorgestrel
TABLET;ORAL-28018782-001Jul 21, 1982► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Branded Pharm
ZIAC
bisoprolol fumarate; hydrochlorothiazide
TABLET;ORAL020186-003Mar 26, 1993► Subscribe► Subscribe
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006► Subscribe► Subscribe
Teva Branded Pharm
NORDETTE-21
ethinyl estradiol; levonorgestrel
TABLET;ORAL-21018668-001May 10, 1982► Subscribe► Subscribe
Teva Branded Pharm
NORDETTE-28
ethinyl estradiol; levonorgestrel
TABLET;ORAL-28018782-001Jul 21, 1982► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Branded Pharm
CENESTIN
estrogens, conjugated synthetic a
TABLET;ORAL020992-001Jun 21, 2002► Subscribe► Subscribe
Teva Branded Pharm
QVAR 40
beclomethasone dipropionate
AEROSOL, METERED;INHALATION020911-002Sep 15, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA drugs

Drugname Dosage Strength Tradename Submissiondate
omacetaxine mepesuccinate
for Injection3.5 mg/vial
SYNRIBO
10/26/2016
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
2/26/2014
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
1/29/2014
levonorgestrel; ethinyl estradiol;ethinyl estradiol
Tablets0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg
QUARTETTE
7/10/2013
rasagiline mesylate
Tablets0.5 mg and 1 mg
AZILECT
5/17/2010
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfa
Tablets5 mg, 10 mg, 20 mg, 30 mg
ADDERALL 30
11/18/2009
levonorgestrel;ethinyl estradiol;ethinyl estradiol
Tablets0.1 mg/0.02 mg and 0.01 mg
LOSEASONIQUE
11/16/2009
conjugated estrogen (synthetic a)
Tablets0.3 mg, 0.45 mg and 0.9 mg
CENESTIN
3/19/2009
conjugated estrogen (synthetic a)
Tablets0.625 mg
CENESTIN
3/2/2009
conjugated estrogen (synthetic a)
Tablets1.25 mg
CENESTIN
11/3/2008
cyclobenzaprine hydrochloride
Extended-release Capsule15 mg and 30 mg
AMRIX
8/11/2008
levonorgestrel; ethinyl estradiol; ethinyl estradiol
Tablets0.15 mg/0.03 mg/0.01 mg
SEASONIQUE
1/22/2008
levonorgestrel and ethinyl estradiol
Tablets0.15 mg/0.03 mg
SEASONALE
3/29/2004

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe
► Subscribe ► Subscribe

Non-Orange Book Patents for Teva

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,454Estrogenic compounds, pharmaceutical compositions and formulations comprising the same► Subscribe
7,619,117Rasagiline formulations and processes for their preparation► Subscribe
9,533,111Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
7,459,445Estrogenic compounds and topical pharmaceutical formulations of the same► Subscribe
7,842,687Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
6,743,413 Suspension aerosol formulations► Subscribe
5,387,612 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease► Subscribe
9,737,674Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
8,338,396Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
7,169,774Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Drugs

Country Document Number Estimated Expiration
Canada2935569► Subscribe
Hong Kong1222127► Subscribe
Japan2005516913► Subscribe
HungaryE032058► Subscribe
Slovakia501352015► Subscribe
New Zealand603466► Subscribe
Spain2544437► Subscribe
Hong Kong1222150► Subscribe
Cyprus1114421► Subscribe
Australia2008237614► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00C/001Belgium► SubscribePRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
C0022France► SubscribePRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
2014 00034Denmark► SubscribePRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220
2016000120Germany► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
2015 00017Denmark► SubscribePRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
02C/035Belgium► SubscribePRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
/2000Austria► SubscribePRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
C/GB98/017United Kingdom► SubscribePRODUCT NAME: PRAMIPEXOLE, OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT, IN PARTICULAR PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/97/050/001 19971014; UK EU/1/97/050/002 19971014; UK EU/1/97/050/003 19971014; UK EU/1/97/050/004 19971014; UK EU/1/97/050/005 19971014; UK EU/1/97/050/006 19971014; UK EU/1/97/050/007 19971014; UK EU/1/97/050/008 19971014; UK EU/1/97/050/009 19971014; UK EU/1/97/050/010 19971014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Mallinckrodt
Federal Trade Commission
Moodys
Daiichi Sankyo
Chubb
QuintilesIMS
Harvard Business School
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot